HOME >> BIOLOGY >> NEWS
ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 19, 2003 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that patients in a phase 3 clinical study assessing the efficacy and tolerability of ENBREL. (etanercept) in the treatment of active ankylosing spondylitis experienced significant and rapid reduction in back pain and morning stiffness, and improvement in spinal mobility and physical function. The data are part of a presentation at the annual meeting of European League Against Rheumatism being held this week in Lisbon, Portugal.

"A significant number of patients treated with ENBREL in this study saw a marked improvement in as early as two weeks after initiation of treatment. Patients reached maximum relief within the first two months of the study and experienced sustained results for the remainder of the six-month study," said Dr. John Davis, assistant professor of medicine at the University of California-San Francisco and associate director of the Department of Medicine Clinical Trials Center. "I am excited about these encouraging results with ENBREL, especially since it is the first treatment to show improvement in AS patients' range of spinal motion in a phase 3 study."

The multi-center, double-blind, placebo-controlled study randomized 277 patients to receive either ENBREL (25 mg twice weekly; n=138) or placebo (n=139) over a 6-month period. The primary endpoint of the pivotal Phase 3 study was the percentage of patients at 12 weeks and 24 weeks achieving a 20 percent improvement in the Assessment in Ankylosing Spondylitis Response Criteria (ASAS 20), a composite measure that includes back pain, inflammation and physical function.

At week 12, 60 percent of patients treated with ENBREL achieved the ASAS 20 compared with 27 percent of patients in the placebo group. At 24 weeks, 58 percent of patients treated with ENBREL achieved the ASAS 20 compared with 23 percent of the placebo pati
'"/>

Contact: Rebecca Hamm, Amgen
805-447-3872
Porter Novelli
20-Jun-2003


Page: 1 2 3 4

Related biology news :

1. ENBREL provided rapid and significant relief for psoriasis patients in second pivotal study
2. Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function
3. ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
4. ENBREL is first therapy approved for psoriatic arthritis
5. New Phase 2 study shows ankylosing spondylitis patients respond to ENBREL (etanercept)
6. Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting
7. Rare mutations can significantly increase risk factor for heart disease
8. Cancer health risk significantly underestimated by EPAs ambient model estimates
9. Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk
10. HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma
11. Cognitive abilities increase significantly with time in most prematurely born children

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):
(Date:5/27/2016)... New Jersey and ... Indegene ( http://www.indegene.com ... und marketingorientierten Lösungen für die Life-Science-Branche, Pharmaunternehmen ... ein bekannter weltweiter Anbieter von innovativen wissenschaftlichen ... Zuge des Starts von IntraScience heute den ...
(Date:5/26/2016)... ISELIN, New Jersey and ... -- Indegene ( http://www.indegene.com ), a ... solutions to life science, pharmaceutical and healthcare organisations ... provider of innovative scientific support throughout the product ... alliance with the launch of IntraScience. ...
(Date:5/26/2016)... ... 26, 2016 , ... After several promising treatments in Panama ... City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient received ... year following FDA approval of a second application for a single patient, investigational ...
(Date:5/25/2016)... ... ... Lajollacooks4u has become a rising hotspot for specialized team building events in ... Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm and Elsevier, have traveled from ... Each event kicks off with an olive oil and salt-tasting competition. From there, ...
Breaking Biology Technology:
Cached News: